Market Exclusive

Applied Genetic Technologies Corp (NASDAQ:AGTC) had its Buy rating reiterated by HC Wainwright with a $12.00 price target

Analyst Ratings For Applied Genetic Technologies Corp (NASDAQ:AGTC)

Today, HC Wainwright reiterated its Buy rating on Applied Genetic Technologies Corp (NASDAQ:AGTC) with a price target of $12.00.

There are 3 Buy Ratings, 2 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Applied Genetic Technologies Corp (NASDAQ:AGTC) is Buy with a consensus target price of $9.60 per share, a potential 138.81% upside.

Some recent analyst ratings include

About Applied Genetic Technologies Corp (NASDAQ:AGTC)
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology. Read More…

Recent Trading Activity for Applied Genetic Technologies Corp (NASDAQ:AGTC)
Shares of Applied Genetic Technologies Corp closed the previous trading session at 4.07 up +0.010 0.25% with 4.08 shares trading hands.

Exit mobile version